Diagnosis and Management of Common Acquired Bleeding Disorders

Abstract

Acquired bleeding disorders (ABD) are commonly encountered in both inpatient and outpatient settings. ABD can occur due to consumption, decreased synthesis, or inhibition of coagulation factors and platelets. Clinical presentation may vary, ranging from mild bruising to life-threatening hemorrhage. The location, frequency, severity, and provocation of bleeding provide insight into the cause of ABD. Obtaining a good medical, surgical, family, social, and medication history is a crucial step in determining the underlying etiology. Basic laboratory parameters, such as prothrombin time, partial thromboplastin time, thrombin time, fibrinogen, platelet count, and D-dimer levels, aid in further elucidating the reason for bleeding. Optimal management depends on accurate interpretation of the history and laboratory values. Treatment options include administration of vitamin K; blood component transfusion, consisting of plasma, cryoprecipitate, and/or platelets; and blood derivatives, including single and multiple factor concentrates. These products should be used judiciously, due to potential infectious and noninfectious complications, including transfusion-related acute lung injury and transfusion-associated circulatory overload. This article discusses the management of the more common causes of ABD.

Keywords

acquired coagulopathy - disseminated intravascular coagulation - liver disease - warfarin reversal - new oral anticoagulants

• References

• 1 van den Besselaar AM. Standardization of the prothrombin time in oral anticoagulant control. Haemostasis 1985; 15 (4) 271-277
• 2 Levi M, Meijers JC. DIC: which laboratory tests are most useful. Blood Rev 2011; 25 (1) 33-37
• 3 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341 (8) 586-592
• 4 Levi M. Disseminated intravascular coagulation: What's new?. Crit Care Clin 2005; 21 (3) 449-467
• 5 Montagnana M, Franchi M, Danese E, Gotsch F, Guidi GC. Disseminated intravascular coagulation in obstetric and gynecologic disorders. Semin Thromb Hemost 2010; 36 (4) 404-418
• 6 Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008; 34 (7) 604-611
• 7 Reddy NM, Hall SW, MacKintosh FR. Partial thromboplastin time: prediction of adverse events and poor prognosis by low abnormal values. Arch Intern Med 1999; 159 (22) 2706-2710
• 8 Levi M. The coagulant response in sepsis. Clin Chest Med 2008; 29 (4) 627-642 , viii
• 9 Bakhtiari K, Meijers JCM, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32 (12) 2416-2421
• 10 Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113 (13) 2878-2887
• 11 Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis 2006; 17 (6) 445-451
• 12 Qu L, Kiss JE, Dargo G, Carcillo JA. Outcomes of previously healthy pediatric patients with fulminant sepsis-induced multisystem organ failure receiving therapeutic plasma exchange. J Clin Apher 2011; 26 (4) 208-213
• 13 Stegmayr B. Apheresis in patients with severe sepsis and multi organ dysfunction syndrome. Transfus Apheresis Sci 2008; 38 (3) 203-208
• 14 Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2012; 3: CD004388
• 15 Levi M, Toh CH, Thachil J, Watson HG. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009; 145 (1) 24-33
• 16 Pandit TN, Sarode R. Blood component support in acquired coagulopathic conditions: is there a method to the madness?. Am J Hematol 2012; 87 (Suppl. 01) S56-S62
• 17 Patel R, Cook DJ, Meade MO , et al. Burden of Illness in venous ThromboEmbolism in Critical care (BITEC) Study Investigators; Canadian Critical Care Trials Group. Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care 2005; 20 (4) 341-347
• 18 Kujovich JL. Hemostatic defects in end stage liver disease. Crit Care Clin 2005; 21 (3) 563-587
• 19 Hollestelle MJ, Thinnes T, Crain K , et al. Tissue distribution of factor VIII gene expression in vivo—a closer look. Thromb Haemost 2001; 86 (3) 855-861
• 20 Hollestelle MJ, Geertzen HGM, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91 (2) 267-275
• 21 Green G, Poller L, Thomson JM, Dymock IW. Factor VII as a marker of hepatocellular synthetic function in liver disease. J Clin Pathol 1976; 29 (11) 971-975
• 22 Green G, Thomson JM, Dymock IW, Poller L. Abnormal fibrin polymerization in liver disease. Br J Haematol 1976; 34 (3) 427-439
• 23 Kelly DA, Tuddenham EG. Haemostatic problems in liver disease. Gut 1986; 27 (3) 339-349
• 24 Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982; 35 (6) 667-672
• 25 Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001; 114 (2) 249-257
• 26 McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Best Pract Res Clin Gastroenterol 2000; 14 (6) 1009-1031
• 27 Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest 1966; 45 (5) 645-657
• 28 Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116 (6) 878-885
• 29 Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104 (1) 96-101
• 30 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (2) 147-156
• 31 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49 (3) 1017-1044
• 32 Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 4 (10) 2115-2129
• 33 Ness PM, Perkins HA. Cryoprecipitate as a reliable source of fibrinogen replacement. JAMA 1979; 241 (16) 1690-1691
• 34 Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49 (6) 1171-1177
• 35 Sarode R, Matevosyan K, Bhagat R, Rutherford C, Madden C, Beshay JE. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg 2012; 116 (3) 491-497
• 36 Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol 2001; 114 (2) 271-280
• 37 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6) (Suppl): 160S-198S
• 38 Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135 (6) 393-400
• 39 Beshay JE, Morgan H, Madden C, Yu W, Sarode R. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. J Neurosurg 2010; 112 (2) 307-318
• 40 Palareti G, Leali N, Coccheri S , et al. Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348 (9025) 423-428
• 41 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105 (2) 91-99
• 42 Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114 (5) (Suppl): 511S-523S
• 43 Wintzen AR, de Jonge H, Loeliger EA, Bots GT. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984; 16 (5) 553-558
• 44 Mathiesen T, Benediktsdottir K, Johnsson H, Lindqvist M, von Holst H. Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatment. Acta Neurol Scand 1995; 91 (3) 208-214
• 45 Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): 7S-47S
• 46 Crowther MA, Douketis JD, Schnurr T , et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137 (4) 251-254
• 47 Keeling D, Baglin T, Tait C , et al; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154 (3) 311-324
• 48 Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis 2010; 29 (2) 171-181
• 49 Turpie AGG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108 (5) 876-886
• 50 Miesbach W, Seifried E. New direct oral anticoagulants—current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012; 108 (4) 625-632
• 51 Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110 (3) 453-460
• 52 Bauer KA. Reversal of antithrombotic agents. Am J Hematol 2012; 87 (Suppl. 01) S119-S126
• 53 van Ryn J, Stangier J, Haertter S , et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6) 1116-1127
• 54 Samama MM, Contant G, Spiro TE , et al. Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107 (2) 379-387
• 55 Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011; 7 (4) 281-287
• 56 Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl. 01) 9S-16S
• 57 Szczepiorkowski ZM, Winters JL, Bandarenko N , et al. Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25 (3) 83-177
• 58 Godier A, Miclot A, Le Bonniec B , et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116 (1) 94-102
• 59 Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost 2007; 98 (4) 790-797
• 60 Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol 2007; 82 (7) 656-660
• 61 Nelson AT, Hartzell JD, More K, Durning SJ. Ingestion of superwarfarin leading to coagulopathy: a case report and review of the literature. MedGenMed 2006; 8 (4) 41
• 62 Bronstein AC, Spyker DA, Cantilena Jr LR, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49 (10) 910-941
• 63 Choufani EB, Sanchorawala V, Ernst T , et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97 (6) 1885-1887
• 64 Furie B, Voo L, McAdam KP, Furie BC. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 1981; 304 (14) 827-830
• 65 Lee G, Duan-Porter W, Metjian A. Acquired, non-amyloid related factor X deficiency: review of the literature. Haemophilia 2012; 18 (5) 655-663
• 66 Barker B, Altuntas F, Paranjape G, Sarode R. Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency. J Clin Apher 2004; 19 (4) 208-210
• 67 Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42 (1) 18-26
• 68 Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia 2008; 14 (6) 1164-1169
• 69 Baca V, Montiel G, Meillón L , et al. Diagnosis of lupus anticoagulant in the lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Am J Hematol 2002; 71 (3) 200-207
• 70 Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61 (4) 684-692
• 71 Simel DL, St Clair EW, Adams J, Greenberg CS. Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med 1987; 83 (3) 563-566
• 72 Vivaldi P, Rossetti G, Galli M, Finazzi G. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica 1997; 82 (3) 345-347
• 73 Konkle BA. Acquired disorders of platelet function. Hematology (Am Soc Hematol Educ Program) 2011; 2011: 391-396
• 74 Harrison P, Mackie I, Mumford A , et al. British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155 (1) 30-44
• 75 Tholouli E, Hay CRM, O'Gorman P, Makris M. Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol 2004; 127 (2) 209-213
• 76 Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 2005; 11 (1) 25-35
• 77 Sarode R. How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect?. Transfusion 2012; 52 (4) 695-701 , quiz 694
• 78 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30 (5) 579-589
• 79 Horowitz HI, Stein IM, Cohen BD, White JG. Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 1970; 49 (3) 336-345
• 80 Livio M, Mannucci PM, Viganò G , et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986; 315 (12) 731-735